Our story

We could change the lives of millions

Since 2008, we’ve been on a mission to save lives through science.

Our ambition is simple really. We want to use our unique T Cell Receptor platform to deliver life changing medicines to patients with unmet clinical need.

We believe this is best achieved in two ways:

By aiming to do this by ourselves, staying independent, as a fully integrated, specialty pharmaceutical company. 

Of course, it makes sense to partner with other leading organisations, for broader disease areas with greater demands on resources. So we’ll be partnering with those organisations who have technologies that complement our own and the resources to ensure as broad a range of patients will benefit from our platform.

dr_bent_color.jpg

This is Dr Bent Jakobsen. He’s kind of our hero.

You see, in 1999 he founded a company called Avidex, as a spinoff from research he’d been doing at the University of Oxford, to develop new T Cell Receptor technology. Avidex did so well that in 2006 it was acquired by a German company called Medigene, who we now like to think of as an older step-sister. 

After two years, it became apparent that our science had the potential for so much more and so two new companies, Adaptimmune and Immunocore were born. So you see, it’s all thanks to those early efforts of our Dr Jakobsen.

tri_masked_image_our_story_woman_smiling_at_table.png

We approach everything a little differently

We’re not your everyday biotech company. We believe it’s our shared mission and open, collegiate-like culture which make us unique. What does that look like and how does it work, we hear you ask? Well we try to keep these five guiding principles in mind with everything we do.

value_icon_torch.svg

Lead with purpose

Everything we do stems from our common goal to help people affected by challenging diseases.

value_icon_ear.svg

Listen to everyone

We’re open, honest and ready to share and learn from each other.

value_icon_multi_arrows.svg

Challenge the status quo

We’re constantly curious and believe we can always learn and improve.

value_icon_chain.svg

Trust in each other

We work together, collaboratively and with mutual respect towards our purpose.

value_icon_shutes.svg

Never give up hope

We’re passionately hopeful about the possibilities before us.

1999

Dr Bent Jakobsen founded Avidex as a spin-off of his research into T Cell Receptors at the University of Oxford.

2006

Avidex is acquired by Medigene AG.

2008

With the help of private investment, we bought back certain technology which Medigene AG had acquired and two new sister companies are founded. At Immunocore, we focus on monoclonal TCRs and at Adaptimmune they focus on adoptive T cell therapy.

2010

We began our very first clinical trial for IMCgp100 in malignant melanoma.

2013

We partnered with GSK to discover and develop multiple novel targets.

2013

Phase IIa of our clinical trial for IMCgp100 in melanoma was started.

2013

We partnered with Genentech to discover and develop multiple novel targets.

2013

We begin a partnership with MedImmune, the global biologics Research and Development arm of AstraZeneca, to co-develop ImmTAC molecules against novel cancer targets.
 

2014

We entered a partnership with Eli Lilly to research, co-discover and co-develop novel T cell-based cancer therapies.
 

2015

We secured a $320m investment in Europe’s largest private life sciences financing round.
 

2015

We were over the moon to win ‘Biotech of the Year’ at the SCRIP awards.
 

2015

We launched a presence in the US with our new office in Philadelphia.
 

2017

The Bill & Melinda Gates Foundation invests up to $40 million in Immunocore to help advance research into the use of our ImmTAV and ImmTAB molecules for the treatment of HIV and Tuberculosis.
 

1999

Dr Bent Jakobsen founded Avidex as a spin-off of his research into T Cell Receptors at the University of Oxford.

2006

Avidex is acquired by Medigene AG.

2008

With the help of private investment, we bought back certain technology which Medigene AG had acquired and two new sister companies are founded. At Immunocore, we focus on monoclonal TCRs and at Adaptimmune they focus on adoptive T cell therapy.

2010

We began our very first clinical trial for IMCgp100 in malignant melanoma.

2013

We partnered with GSK to discover and develop multiple novel targets.

2013

Phase IIa of our clinical trial for IMCgp100 in melanoma was started.

2013

We partnered with Genentech to discover and develop multiple novel targets.

2013

We begin a partnership with MedImmune, the global biologics Research and Development arm of AstraZeneca, to co-develop ImmTAC molecules against novel cancer targets.
 

2014

We entered a partnership with Eli Lilly to research, co-discover and co-develop novel T cell-based cancer therapies.
 

2015

We secured a $320m investment in Europe’s largest private life sciences financing round.
 

2015

We were over the moon to win ‘Biotech of the Year’ at the SCRIP awards.
 

2015

We launched a presence in the US with our new office in Philadelphia.
 

2017

The Bill & Melinda Gates Foundation invests up to $40 million in Immunocore to help advance research into the use of our ImmTAV and ImmTAB molecules for the treatment of HIV and Tuberculosis.
 

"What attracted me most to Immunocore was the clear purpose and focus on the patient at the centre of everything. Our ImmTAC technology platform has the potential to really make a difference to the lives of patients"

A_Hotchkiss_avatar.png

Andrew Hotchkiss

CCO

"I joined Immunocore because of my fascination with the immune system and how the company was engineering it to help patients. Hearing about how our molecules could change lives gets me out of bed in the morning."

Ruth_Martinez-Hague_avatar.png

Ruth Martinez-Hague

Group Leader, Infectious Disease

"It’s important to me to feel connected to the company I work for, to feel pride in what I do and enjoy working there. That’s why I wanted to work at Immunocore and why, 7 months later, I still love my job."

Michelle_Buckingham_avatar.png

Michelle Buckingham

Financial Controller